Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

TGTX stock hub

TG Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TGTXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

6.1B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

TGTX

In the news

Latest news · TGTX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E24.4

P25 12.3P50 18.4P75 33.1

Trailing P/E14.9

P25 14.9P50 23.2P75 38.5

ROE112.6

P25 -105.6P50 -46.5P75 -3.1

ROIC18.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TGTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

239

Groups with data

Currency

USD

Showing 239 of 239 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001001316
Company name	TG Therapeutics, Inc.
Country	United States
Country code	US
Cusip	88322Q108
Employees	399
Employees Change	61%
Employees Change Percent	18.05
Enterprise value	$6.3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1995-12-14
Isin	US88322Q1085
Last refreshed	2026-05-10
Market cap	$6.1B
Market cap category	Mid-Cap
Price	$42.86
Price currency	USD
Rev Per Employee	1,755,260.65x
Sector	Healthcare
Sic	2834
Symbol	TGTX
Website	https://www.tgtherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.6%
EV Earnings	13.67x
EV Sales Forward	8.78x
EV/EBIT	42.23x
EV/EBITDA	42.21x
EV/Sales	9.01x
FCF yield	-0.23%
Forward P/E	24.36x
P/B ratio	10.42x
P/E ratio	14.93x
P/S ratio	8.67x
PE Ratio3 Y	80.08x
PEG ratio	1.61x
PS Forward	8.45x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	21.35%
EBITDA Margin	21.36%
Gross margin	83.05%
Gross Profit	$581.7M
Gross Profit Growth	72.19%
Gross Profit Growth Q	62.76%
Gross Profit Growth3 Y	322.97%
Gross Profit Growth5 Y	276.58%
Net Income	$461.9M
Net Income Growth	1,079.81%
Net Income Growth Q	290.85%
Net Income Growth Quarters	1%
Net Income Growth Years	4%
Pretax Margin	17.46%
Profit Margin	65.95%
Profit Per Employee	$1.2M
Profitable Years	3
ROA	8.55
Roa5y	-14.08
ROCE	11.14
ROE	112.6
Roe5y	-23.37
ROIC	18.89

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	18.31%
Cagr1y	23%
Cagr3y	7.72%
Cagr5y	1.29%
EPS Growth	1,105.5
EPS Growth Q	300
EPS Growth Quarters	1
EPS Growth Years	4
Revenue Growth	81.26x
Revenue Growth Q	69.56x
Revenue Growth Quarters	6x
Revenue Growth Years	3x
Revenue Growth3 Y	333.92x
Revenue Growth5 Y	278.04x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.64
Assets	$1.5B
Cash	$514.4M
Current Assets	$1.1B
Current Liabilities	$187.1M
Debt	$753.6M
Debt EBITDA	$4.97
Debt Equity	$1.29
Equity	$583.1M
Interest Coverage	5.41
Liabilities	$945.7M
Long Term Assets	$441.9M
Long Term Liabilities	$758.6M
Net Cash	$-239.1M
Net Cash By Market Cap	$-3.94
Net Debt EBITDA	$1.6
Net Debt Equity	$0.41
Tangible Book Value	$583.1M
Tangible Book Value Per Share	$4.11
WACC	12.33

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.81
Inventory Turnover	0.83
Net Working Capital	$387.3M
Quick ratio	4.84
Working Capital	$899.9M
Working Capital Turnover	$1.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.27%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	437.09%
1Y total return	22.98%
200-day SMA	31.92
3Y total return	24.99%
50-day SMA	33.09
50-day SMA vs 200-day SMA	50over200
5Y total return	6.62%
All Time High	56.74
All Time High Change	-24.46%
All Time High Date	2021-01-13
All Time Low	1.13
All Time Low Change	3,709.78%
All Time Low Date	2011-12-30
ATR	1.83
Beta	1.68
Beta1y	0.5
Beta2y	0.6
Ch YTD	43.78
High	44.65
High52	44.65
High52 Date	2026-05-08
High52ch	-4.01%
Low	42.26
Low52	25.28
Low52 Date	2025-08-11
Low52ch	69.54%
Ma50ch	29.55%
Premarket Change Percent	0.38
Premarket Price	$43.19
Premarket Volume	2,505
Price vs 200-day SMA	34.28%
RSI	75.1
RSI Monthly	64.01
RSI Weekly	69.46
Sharpe ratio	0.59x
Sortino ratio	1.02
Total Return	2.27%
Tr YTD	43.78
Tr1m	28.36%
Tr1w	26.62%
Tr3m	48.51%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	1
Analyst Price Target Top	$55
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.27
Earnings EPS Estimate Growth	800
Earnings Revenue Estimate	200,833,064x
Earnings Revenue Estimate Growth	66.18x
Operating Income	$149.5M
Operating Income Growth	149.9
Operating Income Growth Q	303.6
Operating margin	21.35
Price target	$51.8
Price Target Change	$20.86
Price Target Change Top	$28.33

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	135,104,730%
Float Percent	95.33%
Net Borrowing	492,656,000
Shares Insiders	4.63%
Shares Institutions	77.2%
Shares Out	141,723,008
Shares Qo Q	0.44%
Shares Yo Y	-2.27%
Short Float	21.26%
Short Ratio	13.35
Short Shares	20.27

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-83.8M
Average Volume	2,273,889.4x
Bv Per Share	4.11
CAPEX	$-240,000
Ch10y	437.1
Ch1m	28.36
Ch1w	26.62
Ch1y	22.98
Ch3m	48.51
Ch3y	24.99
Ch5y	6.62
Ch6m	32.94
Change	-0.4%
Change From Open	-0.37
Close	43.03
Days Gap	-0.02
Depreciation Amortization	83,000
Dollar Volume	159,849,241.6
Earnings Date	2026-05-06
Earnings Time	bmo
EBIT	$149.5M
EBITDA	$149.6M
EPS	$2.87
F Score	3
FCF	$-14.2M
FCF EV Yield	-0.22x
FCF Per Share	$-0.1
Financing CF	307,202,000
Fiscal Year End	December
Founded	1,993
Graham Number	16.3019
Graham Upside	-61.96
Income Tax	$-339.6M
Investing CF	16,869,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Date	2012-04-30
Last Split Type	Reverse
Last10k Filing Date	2026-02-27
Ma150	32
Ma150ch	33.93%
Ma20	36.43
Ma20ch	17.67%
Net CF	310,120,000
Next Earnings Date	2026-08-03
Open	43.02
Optionable	Yes
Position In Range	25.1
Post Close	42.86
Postmarket Change Percent	0.85
Postmarket Price	$43.23
Ppne	6,481,000
Pre Close	43.03
Price Date	2026-05-08
Price EBITDA	$40.61
Ptbv Ratio	10.42
Relative Volume	1.64x
Revenue	700,349,000x
SBC By Revenue	9.94x
Share Based Comp	69,648,000
Tax By Revenue	-48.49x
Tr6m	32.94%
Us State	North Carolina
Volume	3,729,567
Z Score	3.61

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TGTX pay a dividend?

Capital-return profile for this ticker.

Performance

TGTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TGTX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+77.2%

Float: +95.3% of shares outstanding

Insider ownership

+4.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TGTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

75.1

Above 70: short-term overbought

Price vs 200-day MA

+34.3%

50/200-day relationship not available

Beta (5Y)

1.68

More volatile than the market

Sharpe ratio

0.59

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TGTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TGTX stock rating?

TG Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TGTX analysis?

The full report lives at /stocks/TGTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TGTX?

The latest report frames TGTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TGTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.